1. Home
  2. ZYME vs VZLA Comparison

ZYME vs VZLA Comparison

Compare ZYME & VZLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • VZLA
  • Stock Information
  • Founded
  • ZYME 2003
  • VZLA 2017
  • Country
  • ZYME United States
  • VZLA Canada
  • Employees
  • ZYME N/A
  • VZLA N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • VZLA
  • Sector
  • ZYME Health Care
  • VZLA
  • Exchange
  • ZYME Nasdaq
  • VZLA Nasdaq
  • Market Cap
  • ZYME 968.5M
  • VZLA 1.1B
  • IPO Year
  • ZYME 2017
  • VZLA N/A
  • Fundamental
  • Price
  • ZYME $15.93
  • VZLA $3.99
  • Analyst Decision
  • ZYME Buy
  • VZLA Strong Buy
  • Analyst Count
  • ZYME 7
  • VZLA 1
  • Target Price
  • ZYME $20.00
  • VZLA $3.25
  • AVG Volume (30 Days)
  • ZYME 446.6K
  • VZLA 3.2M
  • Earning Date
  • ZYME 10-30-2025
  • VZLA 09-08-2025
  • Dividend Yield
  • ZYME N/A
  • VZLA N/A
  • EPS Growth
  • ZYME N/A
  • VZLA N/A
  • EPS
  • ZYME N/A
  • VZLA N/A
  • Revenue
  • ZYME $122,867,000.00
  • VZLA N/A
  • Revenue This Year
  • ZYME $107.76
  • VZLA N/A
  • Revenue Next Year
  • ZYME $2.35
  • VZLA N/A
  • P/E Ratio
  • ZYME N/A
  • VZLA N/A
  • Revenue Growth
  • ZYME 95.94
  • VZLA N/A
  • 52 Week Low
  • ZYME $9.03
  • VZLA $1.67
  • 52 Week High
  • ZYME $17.70
  • VZLA $4.00
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 64.90
  • VZLA 68.31
  • Support Level
  • ZYME $14.88
  • VZLA $3.62
  • Resistance Level
  • ZYME $16.37
  • VZLA $4.00
  • Average True Range (ATR)
  • ZYME 0.65
  • VZLA 0.17
  • MACD
  • ZYME 0.11
  • VZLA 0.02
  • Stochastic Oscillator
  • ZYME 84.12
  • VZLA 98.23

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About VZLA Vizsla Silver Corp.

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

Share on Social Networks: